RXR agonists activate RXR/LXR and PPAR/RXR heterodimers, promote ABCA1 and ApoE mRNA expression in cells, reduce Aβ levels, and thereby reverse cognitive impairments in AD [221, 222]. Here, ABCA1 is linked to Alzheimer disease.